Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Blood|April 14, 2012
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaMichele Cavo, Lucia Pantani, Maria Teresa Petrucci, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Eclinicalmedicine|July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trialElena Zamagni, Stefania Oliva, Francesca Gay, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' projectFrancesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
The Lancet. Haematology|January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trialAndrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
European Journal of Haematology|January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' RecommendationsAlessandro Corso, Monia Marchetti, Monica Galli, et al.
Cancer Medicine|March 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization ExperienceStefania Oliva, Marina Martello, Elona Saraci, et al.
Haematologica|April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patientsGregorio Barilà, Angela Grassi, Concetta Conticello, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Pageof 15